BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype – homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor. The patent (USP# 8,080,578) entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting,” provides protection in the United States for this novel approach to treating patients with bucindolol.  

PhamaJet Inc. (Golden,CO.) has completed a clinical study using its novel, needle-free, FDA-approved jet injection device in comparison to needle and syringe for the administration of rabies vaccine. According to Dr. Daniel Perlman, Principal Investigator, 100% of the volunteers achieved protective immunity, and the study demonstrated the device to be safe and easy to use. Rabies remains a significant public health issue, causing about 50,000 deaths annually globally.  The PharmaJet technology improves safety by eliminating needle-stick injuries to health care providers and also eliminates the cost and environmental impact of needle waste disposal.  

Results from ImagistxProstate™ Ultra High Resolution Ultrasound Study at Johns Hopkins Hospital Show Significant Increase in Prostate Cancer Detection  

Centennial, CO (December 19, 2011) – LABS, Inc., a global, full-service testing laboratory with more than 30 years of expertise in regulated testing for human organs, cells, tissues and implantable biologic products and devices, was this month named Company of the Year by the 2011 Colorado BioScience Association (CBSA) Annual Awards. The awards program showcases and honors individuals and companies that have made a significant difference to Colorado’s bioscience industry during the past year. 

December 15, 2011 07:00 AM Eastern Time
Covidien Plans Spin-Off of Pharmaceuticals Business
DUBLIN--(BUSINESS WIRE)--Covidien plc (NYSE: COV), a leading global provider of healthcare products, today announced that it plans to spin off its pharmaceuticals business into a standalone public company.  

Fitzsimons Redevelopment Authority Announces Second Phase of Strategic Refocus With
$8 Million Expansion to Bioscience Park Center with 37,000‐Square‐Foot Accelerator Facility 

Denver Business Journal by Greg Avery, Reporter  

Continue Reading

Quoting from the CSU News website: